BioLineRx (BLRX) News Today → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Free BLRX Stock Alerts $0.64 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 5:00 PM | prnewswire.comBioLineRx Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 11, 2024 | marketbeat.comShort Interest in BioLineRx Ltd. (NASDAQ:BLRX) Drops By 47.6%BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totalling 410,600 shares, a decline of 47.6% from the April 15th total of 783,600 shares. Based on an average daily volume of 416,500 shares, the days-to-cover ratio is currently 1.0 days.May 6, 2024 | prnewswire.comBioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024April 18, 2024 | markets.businessinsider.comBuy Rating on Bioline RX Ltd for Breakthrough Stem Cell Mobilization and Enhanced Apheresis EfficiencyApril 17, 2024 | finance.yahoo.comBioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual MeetingApril 12, 2024 | marketbeat.comBioLineRx (NASDAQ:BLRX) Rating Increased to Sell at StockNews.comStockNews.com upgraded shares of BioLineRx to a "sell" rating in a research report on Friday.April 11, 2024 | investing.comBioLineRx secures $20 million in BlackRock financingApril 10, 2024 | finance.yahoo.comBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing AgreementApril 10, 2024 | prnewswire.comBioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing AgreementApril 1, 2024 | prnewswire.comBioLineRx Announces $6 Million Registered Direct OfferingMarch 29, 2024 | marketbeat.comFY2024 Earnings Forecast for BioLineRx Ltd. (NASDAQ:BLRX) Issued By HC WainwrightBioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Investment analysts at HC Wainwright cut their FY2024 earnings estimates for BioLineRx in a report issued on Tuesday, March 26th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($1.03) per share forMarch 28, 2024 | marketbeat.comShort Interest in BioLineRx Ltd. (NASDAQ:BLRX) Expands By 76.6%BioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a significant increase in short interest in March. As of March 15th, there was short interest totalling 324,700 shares, an increase of 76.6% from the February 29th total of 183,900 shares. Based on an average daily trading volume, of 316,300 shares, the days-to-cover ratio is presently 1.0 days.March 28, 2024 | finanznachrichten.deBioLineRx Ltd.: BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio UpdatesMarch 28, 2024 | marketbeat.comResearch Analysts Issue Forecasts for BioLineRx Ltd.'s Q1 2024 Earnings (NASDAQ:BLRX)BioLineRx Ltd. (NASDAQ:BLRX - Free Report) - Analysts at HC Wainwright issued their Q1 2024 earnings estimates for shares of BioLineRx in a research note issued to investors on Tuesday, March 26th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($0.29) per sMarch 27, 2024 | marketbeat.comBioLineRx (NASDAQ:BLRX) Upgraded to Sell at StockNews.comStockNews.com upgraded shares of BioLineRx to a "sell" rating in a report on Wednesday.March 27, 2024 | finance.yahoo.comBioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comBLRX: First Aphexda Sales RecognizedMarch 27, 2024 | marketbeat.comBioLineRx (NASDAQ:BLRX) Announces Earnings ResultsBioLineRx (NASDAQ:BLRX - Get Free Report) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. The business had revenue of $4.80 million for the quarter, compared to analyst estimates of $0.17 million. During the same quarter in the prior year, the firm earned ($0.09) EPS.March 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst OptimismMarch 26, 2024 | marketbeat.comBioLineRx's (BLRX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $21.00 price target on shares of BioLineRx in a research note on Tuesday.March 26, 2024 | prnewswire.comBioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio UpdatesMarch 21, 2024 | marketbeat.comBioLineRx (BLRX) to Release Quarterly Earnings on TuesdayBioLineRx (NASDAQ:BLRX) will be releasing earnings before the market opens on Tuesday, March 26, Zacks reports.March 20, 2024 | prnewswire.comBioLineRx to Report 2023 Annual Financial Results on March 26, 2024March 19, 2024 | marketbeat.comBioLineRx Ltd. (NASDAQ:BLRX) Sees Large Decrease in Short InterestBioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) was the target of a large decline in short interest during the month of February. As of February 29th, there was short interest totalling 183,900 shares, a decline of 8.1% from the February 14th total of 200,000 shares. Based on an average trading volume of 313,400 shares, the days-to-cover ratio is currently 0.6 days.March 4, 2024 | finance.yahoo.comBioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale ProductionMarch 1, 2024 | investing.comBioLineRx begins phase 2 trial for pancreatic cancer treatmentMarch 1, 2024 | finance.yahoo.comBLRX Mar 2024 1.000 callFebruary 28, 2024 | prnewswire.comBioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)February 26, 2024 | finance.yahoo.comBLRX: Poster PresentationsFebruary 25, 2024 | investorplace.com3 Top Penny Stocks for 5,000% Upside in 2024 and BeyondFebruary 23, 2024 | ca.finance.yahoo.comBLRX May 2024 1.000 putFebruary 16, 2024 | finance.yahoo.comBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®February 16, 2024 | prnewswire.comBioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®December 29, 2023 | marketbeat.comBioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Drop in Short InterestBioLineRx Ltd. (NASDAQ:BLRX - Get Free Report) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 114,800 shares, a decrease of 59.2% from the November 30th total of 281,100 shares. Based on an average daily trading volume, of 430,400 shares, the days-to-cover ratio is presently 0.3 days.December 21, 2023 | finance.yahoo.comBioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell DiseaseDecember 4, 2023 | seekingalpha.comBioLineRx: Still A Buy, With Some QuestionsDecember 3, 2023 | seekingalpha.comBioLineRx: Weighing Aphexda's Breakthrough Against Financial ChallengesNovember 21, 2023 | insidermonkey.comBioLineRx Ltd. (NASDAQ:BLRX) Q3 2023 Earnings Call TranscriptNovember 21, 2023 | markets.businessinsider.comBioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future GrowthNovember 21, 2023 | finance.yahoo.comBLRX: A Series of Fortunate EventsNovember 20, 2023 | finance.yahoo.comBioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio UpdatesNovember 17, 2023 | msn.combiolinerx Q3 2023 Earnings PreviewNovember 13, 2023 | finance.yahoo.comBioLineRx to Report Third Quarter 2023 Results on November 20, 2023November 5, 2023 | msn.comWeek In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7BNovember 2, 2023 | marketwatch.comBioLineRx Shares Rise 12% After Licensing Agreement for MotixafortideOctober 31, 2023 | finanznachrichten.deMSQ Ventures: BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesOctober 31, 2023 | finance.yahoo.comBioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesOctober 12, 2023 | markets.businessinsider.comBioLineRx Concludes License Deal With Guangzhou Gloria To Develop Motixafortide In AsiaOctober 12, 2023 | finance.yahoo.comBioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity InvestmentOctober 9, 2023 | thestreet.comBioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Guard Against the Coming Financial Upheaval (Ad)America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late. You can stream it for free right here. BLRX Media Mentions By Week BLRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLRX News Sentiment▼0.000.42▲Average Medical News Sentiment BLRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLRX Articles This Week▼11▲BLRX Articles Average Week Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ELDN News Today GANX News Today AADI News Today CELU News Today RPHM News Today ANVS News Today IMMX News Today CLNN News Today CALC News Today OCUP News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersDon’t expose yourself to stocks during the weekDTIRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHas Trump Finally Gone Too Far?Insiders ExposedDoes this make you sick?Allegiance GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHow this is some devastating newsWealthPress Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
